Endo International | ENDP - Beneficio Bruto En Ventas



Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 10.47B 605M 2025-09
Amarin USD 22.21M 28.15M 2025-09
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
Bristol-Myers Squibb USD 8.79B 110M 2025-09
Coherus Biosciences USD 4.95M 15.34M 2025-03
Eli Lilly USD 14.59B 1.48B 2025-09
Heron Therapeutics USD 23.35M 1.6M 2024-09
Hikma Pharmaceutical USD 362.5M 329.5M 2025-06
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
Merck USD 13.42B 431M 2025-09
Novartis USD 10.82B 695M 2025-09
Pacira USD 142.25M 11.34M 2025-12
Perrigo USD 362.2M 14.9M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
Phibro Animal Health USD 101.87M 18.38M 2024-12
Supernus Pharmaceuticals USD 164.04M 15.23M 2025-12
Takeda JPY 790.55B 262.97B 2025-12
Teva Pharmaceutical Industries USD 2.66B 351M 2025-12
Xeris Pharmaceuticals USD 63.38M 3.74M 2025-09
Zoetis USD 1.64B 73M 2025-12